The DOI matches its Crossref record.
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Open accessAbstract
The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. Whereas drug treatment has been shown to be superior in first-line treatment, data on allogeneic hematopoietic stem cell transplantation (allo SCT) as second-line therapy after imatinib failure are scarce. Using an interim safety analysis of the randomized German CML Study IV designed to optimize imatinib therapy by combination, dose escalation, and transplantation, we here report on 84 patients who underwent consecutive transplantation according to predefined criteria (low European Group for Blood and Marrow Transplantation [EBMT] score, imatinib failure, and advanced disease). Three-year survival after transplantation of 56 patients in chronic phase was 91% (median follow-up: 30 months). Transplantation-related mortality was 8%. In a matched pair comparison of patients who received a transplant and those who did not, survival was not different. Three-year survival after transplantation of 28 patients in advanced phase was 59%. Eighty-eight percent of patients who received a transplant achieved complete molecular remissions. We conclude that allo SCT could become the preferred second-line option after imatinib failure for suitable patients with a donor. The study is registered at the National Institutes of Health, http://clinicaltrials.gov: NCT00055874.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationHanfstein, B., Müller, M. C., Hehlmann, R., Erben, P., Lauseker, M., Fabarius, A., Schnittger, S., Haferlach, C., Göhring, G., Proetel, U., et al. (2012) · Leukemia · doi:10.1038/leu.2012.85 · Cited by 415
Self-citationApperley, J. F. (2015) · The Lancet · doi:10.1016/s0140-6736(13)62120-0 · Cited by 381
Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Müller, M. C., Pletsch, N., Proetel, U., Haferlach, C., Schlegelberger, B., Balleisen, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0598 · Cited by 323
Self-citationHehlmann, R., Müller, M. C., Lauseker, M., Hanfstein, B., Fabarius, A., Schreiber, A., Proetel, U., Pletsch, N., Pfirrmann, M., Haferlach, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.9020 · Cited by 300
Self-citation
Metadata
- Authors
- Saussele, S., Lauseker, M., Gratwohl, A., Beelen, D. W., Bunjes, D., Schwerdtfeger, R., Kolb, H.-J., Ho, A. D., Falge, C., Holler, E., Schlimok, G., Zander, A. R., Arnold, R., Kanz, L., Dengler, R., Haferlach, C., Schlegelberger, B., Pfirrmann, M., Müller, M. C., Schnittger, S., Leitner, A., Pletsch, N., Hochhaus, A., Hasford, J., Hehlmann, R., & for the German CML Study Group
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-03-11
- Volume
- 115
- Issue
- 10
- Pages
- 1880-1885
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2090896574
- Cited by
- 216
- References
- 0
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. https://app.cochat.ai/papers/10.1182/blood-2009-08-237115
- The paper
- Saussele, S., Lauseker, M., Gratwohl, A., Beelen, D. W., Bunjes, D., Schwerdtfeger, R., Kolb, H.-J., Ho, A. D., Falge, C., Holler, E., Schlimok, G., Zander, A. R., Arnold, R., Kanz, L., Dengler, R., Haferlach, C., Schlegelberger, B., Pfirrmann, M., Müller, M. C., . . . for the German CML Study Group. (2010). Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. https://doi.org/10.1182/blood-2009-08-237115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.